University of North Dakota

UND Scholarly Commons
Physician Assistant Scholarly Project Posters

Department of Physician Studies

2019

Managing Anxiety with Pharmacogenomic Testing
Ashley Pommer
University of North Dakota

Follow this and additional works at: https://commons.und.edu/pas-grad-posters
Part of the Psychiatric and Mental Health Commons
Recommended Citation
Pommer, Ashley, "Managing Anxiety with Pharmacogenomic Testing" (2019). Physician Assistant Scholarly Project Posters. 151.
https://commons.und.edu/pas-grad-posters/151

This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for
inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please
contact zeineb.yousif@library.und.edu.

Managing Anxiety with Pharmacogenomic Testing
Ashley Pommer, BS, NRP, PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract

Research Question

Discussion

Anxiety affects approximately three to seven percent of the United
States population, and nearly 50% of the diagnosed patients fail to
respond to first-line treatment regimens (Boland, Duffy, & Meyer
2018). Traditional first-line treatments include medication therapy,
cognitive behavioral therapy (CBT), or the combination of both. With
such a high initial failure rate, recent studies indicate promising results
in managing anxiety with pharmacogenomic testing.
Pharmacogenomic testing is allowing providers to prescribe
medication based on individual genetic makeup, focusing on how each
patient metabolizes certain medications. The purpose of this literature
review was to determine if first-line methods or pharmacogenomic
testing provide patients with more prompt symptom relief. Through a
review of several electronic databases and articles, pharmacogenomic
testing is yielding promising results in symptom relief, decreasing
healthcare costs, and increasing healthcare efficacy. Not only is
pharmacogenomic testing promising for anxiety management, it also
gives insight to several other medication classes. With this
information, pharmacogenomic testing may soon be a screening tool in
future medicine.
Keywords: anxiety, pharmacogenomic testing, anxiety management,
first-line anxiety treatment, pharmacogenetic testing

 In treating anxiety, do those who elect to have pharmacogenomic
testing versus those who are treated based on first-line treatments have
better symptom management?
 In managing anxiety, would patients who respond to pharmacogenetic
testing have decreased healthcare costs and improve overall healthcare
efficacy in comparison to those who trial several medications?

Introduction

Literature Review

• In treating anxiety, do those who elect to have
pharmacogenomic testing versus those who are treated based
on first-line treatments have better symptom management?
– Combination therapy provided no additional benefit
• Patients often refuse
– Only 50.6% of patients remain on first-line provider preference
after pharmacogenetic testing was completed (Boland et al.,
2018).
– Genetic variation plays a major role in medication metabolism
• Those with SLC6A4 and MTHFR genotype do not metabolize
traditional first-line SSRI and SNRI medications (Boland et
al., 2018). Therefore, would fail many first-line medication
trials.
– Bradley et al. (2018), also showed promising statistical benefits
of pharmacogenetic testing.
• Patients classified to have moderate to severe anxiety showed
a reduction in anxiety symptoms when they were prescribed
medications based off NeuroIdgenetix® guided treatment.
• Providers made less changes to medications to those who had
the genetic testing done in comparison to those who were
prescribed provider preference medications (Bradley et al.,
2018).
• In managing anxiety, would patients who respond to
pharmacogenomic testing have decreased healthcare costs and
improve overall healthcare efficacy in comparison to those who
trial several medications?
– In comparing healthcare costs of first-line methods versus results
from pharmacogenetic testing, studies indicate decreased health
care costs for those who receive pharmacogenetic testing.

According to DynaMed Plus (2018), “Anxiety is characterized by
chronic, unfocused, excessive worry and stress associated with clinically
significant distress and functional impairment, often accompanied by
insomnia, restlessness, muscle tension, and concentration problems.”
Anxiety affects approximately three to seven percent of the United States
population, and nearly 50% of those affected fail to respond to first-line
treatment regimens, such as medication and/or therapy (Boland et al.,
2018). Failed treatment can be influenced by environment exposures,
nutrition, co-morbidities, severity of disease, and medication interactions
(Lee, 2018).

http://mayoresearch.mayo.edu/center-for-individualized-medicine/drug-gene-testing.asp

Statement of the Problem
Underdiagnosis of anxiety is quite common, with an average patient
seeing 10 healthcare professionals before a definitive diagnosis is made,
which can lead to increased health care costs in comparison to other
disorders (Lee, 2018). According to Genome Wide Association Studies
(GWAS), genetic variation alone accounts for 42% of varied first-line
therapy response (Boland et al., 2018). Due to a person’s genetic makeup, patients are not being prescribed the most effective medication given
their deoxyribonucleic acid (DNA). With such a high initial failure rate,
pharmacogenomic testing has become an area of research. With this
research, it is thought patients can experience symptom relief upon initial
treatment, prevent future relapse, reduce healthcare costs, and improve
overall healthcare efficacy.

Winner, J., Allen, J. D., Altar, C. A., & Spahic-Mihajlovic, A. (2013). Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and
depression. Translation Psychiatry, 3(3), 242. https://doi.org/10.1038/tp.2013.2

• First-line Treatment for Anxiety
– SSRI medication, CBT, or the combination of both
– Many individuals decline CBT
– 50% of individuals fail first-line treatment methods
• Individual responses vary to treatment making management
difficult
• Pharmacogenomic Testing in Managing Anxiety
– Of the 50% of individuals who fail first-line treatment methods,
50% of those fail due to genetic variation.
– Testing allows providers to prescribe medications based on each
individual DNA
• Research is focusing on CYP450 gene which is responsible for
oxidation of antidepressant medications.
• Those with SLC6A4 and MTHFR genotype benefit from
pharmacogenomic testing, by eliminating drugs that will not
produce effective metabolism.
• CYP2D6 is commonly found in Caucasians vs African
Americans leading to different medication regimens
• Cost Comparison in Pharmacogenomic Testing Versus First-line
Methods
– A trial with IDgenetix® showed a $535 cost saving over a threeyear period in those who elected to have pharmacogenetic
testing.
– Brown et al., (2017) concluded that those who received
pharmacogenomic testing saved $3,988 within that testing year
• This was an extension of a trial which concluded $1,036 in
yearly medical costs
– Winner et al., (2017) trial concluded pharmacogenetic testing can
lead to decreased direct and indirect healthcare utilization and
cost
• Those prescribed medication marked “use with caution with
more frequent monitoring” had more general medical visits,
along with more sick days, and more disability claims

– Those who were part of the CALM trial saw an increase in
healthcare costs of $245 over an 18-month period (Joesch et al.,
2013). These patients received medications based off first-line
medication treatment and were offered CBT. While those who
had IDgenetix® pharmacogenetic testing saw a decrease of $535
in healthcare costs over a three-year period (Najafzaheh et al.,
2017).
– Winner et al. (2013) also supports decreased healthcare costs for
those who are treated based on pharmacogenetic testing.
• Those who received medication labeled “use with caution and
frequent monitoring” saw a significant increase in treatment
costs, more general medical visits, more psychiatric visits,
increase in disability claims, decreased productivity, and
missed work (Winner et al., 2013).
• Those who were treated with “use with caution” or “use as
directed” medications equally both saw decreased healthcare
costs and increased healthcare efficacy with decreased medical
and psychiatric visits. (Winner et al., 2013).

Applicability to Clinical
Practice
Understanding how genetic testing works and implicating those results
into practice is promising for future medicine. Mills, Voora, Payser, &
Haga (2013). Since this is a relatively new therapeutic option,
providers are not familiar with the test’s interpretation (Mills et al.,
2013). Therefore, providers are not offering this option to their
patients. Integrating pharmacogenetic testing into primary care is the
most critical specialty as that is where most medications are
prescribed.
• Providers should become familiar with the tests interpretation
• Discuss with patients the purpose of the test
– The roles genes play in medication metabolism
• Risk vs Benefit
• Limitations
• Future benefits the test has to offer
– Providers will know how a certain medications will metabolize
leading to quicker symptom relief for many conditions
– Will also allow for a warning to patients of certain side effects
With more research, it appears pharmacogenetic testing could be
standard of care as a screening tool not only for anxiety medications
but for several other health conditions. Once a patient is tested,
clinicians will know how several different classes of medications work
based on an individual’s genetic makeup. Thus, reducing the trial and
error method of medication management, decreasing healthcare costs,
and increasing healthcare efficacy.
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